Edgar Filing: LA JOLLA PHARMACEUTICAL CO - Form 8-K

LA JOLLA PHARMACEUTICAL CO Form 8-K May 11, 2011

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of Earliest Event Reported):

[] Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

[] Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) [] Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

May 10, 2011

La Jolla Pharmaceutical Company

(Exact name of registrant as specified in its charter)

Delaware	0-24274	33-0361285
(State or other jurisdiction of incorporation)	(Commission File Number)	(I.R.S. Employer Identification No.)
4365 Executive Drive, Suite 300, San Diego, California		92121
(Address of principal executive offices)		(Zip Code)
Registrant s telephone number, including area	code:	(858) 452-6600
	Not Applicable	
Former name or	former address, if changed since	last report
Check the appropriate box below if the Form 8-K filing is the following provisions:	intended to simultaneously satisfy	the filing obligation of the registrant under any of
[] Written communications pursuant to Rule 425 under the	he Securities Act (17 CFR 230.42	5)

Edgar Filing: LA JOLLA PHARMACEUTICAL CO - Form 8-K

Top of the Form

Item 8.01 Other Events.

On May 10, 2011, La Jolla Pharmaceutical Company (the Company) reported that on that date it had converted approximately 11 shares of Series C-1¹ Convertible Preferred Stock into 1,848,996 shares of common stock. Following these conversions, the Company had a total of 4,014,327 shares of common stock issued and outstanding.

Edgar Filing: LA JOLLA PHARMACEUTICAL CO - Form 8-K

Top of the Form

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

La Jolla Pharmaceutical Company

May 10, 2011 By: /s/ Gail A. Sloan

Name: Gail A. Sloan

Title: Chief Financial Officer and Secretary